title: Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention.
abstract: BACKGROUND
  The aim of the study was to evaluate and compare the efficacy of standard unfractionated heparin (UFH) and low-molecular weight heparins (LMWH's).
  
  
  METHODS
  We modified a previously published rabbit model of arterial thrombosis prevention [1,2] to compare unfractionated heparin and two different doses of two low-molecular weight heparin fragments--nadroparin and enoxaparin. Thrombosis in the distal aorta was triggered by vessel wall injury and critical stenosis. Blood flow in the damaged arterial segment was monitored by a flow probe placed distal to the constrictor. The primary endpoints of the study were: (1) cumulative flow, (2) time to occlusion and (3) residual clot weight. Thirty six animals were split into 6 groups with six animals in each group. Control groups were given saline or heparin and four more groups were used to compare LMWH's at 2 different doses.
  
  
  RESULTS
  In our study, all treatments were superior to the saline control group (alpha<or=0,01). Standard heparin was inferior (alpha<or=0,05) to both low molecular weight heparins for all primary endpoints (cumulative flow, time to occlusion and residual clot weight). There were no differences between the LMWH's except for cumulative flow at high doses.
  
  
  CONCLUSIONS
  This study revealed no relevant differences between nadroparin and enoxaparin for the primary endpoints of our model. Clinical use of each drug remains a personal preference.
authors.affiliation: University of Veterinary and Pharmaceutical Sciences Brno, and st. Ann's Faculty Hosital Brno, Czech Republic. vlasinm@vfu.cz
authors.forename: Michal
authors.initials: M
authors.lastname: Vlasin
authors.forename: Martin
authors.initials: M
authors.lastname: Dvorak
authors.forename: Martina
authors.initials: M
authors.lastname: Dvorakova
authors.forename: Petr
authors.initials: P
authors.lastname: Rauser
authors.forename: Leona
authors.initials: L
authors.lastname: Lexmaulova
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Gregor
mesh_terms: D000818:Animals; D001158:Arteries; D002986:Clinical Trials as Topic; D017984:Enoxaparin / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D008297:Male; D017762:Nadroparin / Q000627:therapeutic use; D011817:Rabbits; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D006493:Heparin